| Parameter | Immunohistochemistry cohort |
|---|---|
| Patients n | 59 |
| Age at diagnosis (range) | 47 (19-75) |
| Sex | |
| Female | 37 (63 %) |
| Male | 20 (34 %) |
| unknown | 2 (3 %) |
| ENSAT Stage (I-IV) | |
| I | 4 (7 %) |
| 27 (46 %) | |
| 15 (25 %) | |
| IV | 11 (19 %) |
| unknown | 2 (3 %) |
| Hormone status | |
| Inactive | 14 (24 %) |
| GC | 15 (26 %) |
| A | 3 (5 %) |
| multiple | 10 (17 %) |
| unknown | 16 (28 %) |
| R-status (ENSAT I-III) 0 1 | unknown |
| 2 | |
| Ki-67 index n (%) | |
| <10 | 17 (28 %) |
| ≥10 | 29 (50 %) |
| unknown | 13 (22 %) |
Colon LEF-1
50 M
2 mm
50 UM
Figure S1. LEF-1 protein expression by immunohistochemistry in healthy colon tissue
Consecutive tissue slices were stained for LEF-1. LEF1 expression is clearly expressed predominantly in the goblet cells of the crypt with exclusive nuclear expression of the epithelial cells.
A
CD3+ T cells
30
Number of samples [n]
p = 0.8050
CD3+ T cells (number/HPF)
150
Correlation of H scores
20
148-
R2=0.0107
146
144
100
10
50
0
0
low
intermediate
high
0
100
200
300
GR
GR
C
CD8+ T cells
30
Number of samples [n]
p = 0.8698
20
CD8+ T cells (number/HPF)
150-
Correlation of H scores R2=0.0089
140-
130
120
60
10
40-
20
0
0
low
intermediate
high
0
100
200
300
GR
GR
☐ low
☒ intermediate
☒ high
B
CD4+ T cells
30
p = 0.3439
Number of samples [n]
30-
Correlation of H scores
20
R2=0.0019
20
10.
CD4+ T cells (number/HPF)
10-
0
0
0
100
200
300
low
intermediate
high
GR
GR
D
FoxP3+ T cells
30
Number of samples [n]
p = 0.4645
FoxP3+ T cells (number/HPF)
30-
Correlation of H scores R2=0.0071
20
25
20-
15
10
10
6
4.
2.
0
0
low
intermediate
high
0
100
200
300
GR
GR
A
LEF-1
CTNNB1
15
15
Number of samples [n]
p = 0.3562
Number of samples [n]
p = 0.4788
10
B
10
5
5
0
0
inactive GCA other
inactive GCA other
☐ low
☒ intermediate
☒ high
C
GR
10
Number of samples [n]
8
p = 1
6
4
2
0
inactive GCA other
| CD3 LEF-1 | low | intermediate | high |
|---|---|---|---|
| low | 7 | 6 | 8 |
| intermediate | 8 | 5 | 6 |
| high | 6 | 9 | 7 |
| CD4 LEF-1 | low | intermediate | high |
|---|---|---|---|
| low | 8 | 5 | 8 |
| intermediate | 9 | 5 | 5 |
| high | 5 | 9 | 8 |
| CD8 LEF-1 | low | intermediate | high |
|---|---|---|---|
| low | 7 | 7 | 7 |
| intermediate | 8 | 7 | 4 |
| high | 6 | 5 | 11 |
| FoxP3 LEF-1 | low | intermediate | high |
|---|---|---|---|
| low | 9 | 2 | 10 |
| intermediate | 7 | 2 | 10 |
| high | 8 | 5 | 9 |
| CD3 CTNNB1 | low | intermediate | high |
|---|---|---|---|
| low | 6 | 2 | 13 |
| intermediate | 7 | 4 | 5 |
| high | 8 | 14 | 3 |
| CD4 CTNNB1 | low | intermediate | high |
|---|---|---|---|
| low | 8 | 3 | 10 |
| intermediate | 6 | 4 | 6 |
| high | 8 | 12 | 5 |
| CD8 CTNNB1 | low | intermediate | high |
|---|---|---|---|
| low | 6 | 5 | 10 |
| intermediate | 7 | 5 | 4 |
| high | 8 | 9 | 8 |
| FoxP3 CTNNB1 | low | intermediate | high |
|---|---|---|---|
| low | 9 | 1 | 11 |
| intermediate | 5 | 0 | 11 |
| high | 10 | 8 | 7 |
| CD3 GR | low | intermediate | high |
|---|---|---|---|
| low | 8 | 6 | 5 |
| intermediate | 6 | 5 | 8 |
| high | 7 | 9 | 8 |
| CD4 GR | low | intermediate | high |
|---|---|---|---|
| low | 9 | 2 | 8 |
| intermediate | 5 | 4 | 10 |
| high | 8 | 1 | 15 |
| CD8 GR | low | intermediate | high |
|---|---|---|---|
| low | 8 | 5 | 6 |
| intermediate | 6 | 7 | 6 |
| high | 7 | 7 | 10 |
| FoxP3 GR | low | intermediate | high |
|---|---|---|---|
| low | 10 | 1 | 8 |
| intermediate | 5 | 4 | 10 |
| high | 9 | 4 | 11 |
A
300
GR expression (H-score)
200
100
0
0
50
100
150
200
250
LEF-1 expression (H-score)
B
300
GR expression (H-score)
200
100
0
0
100
200
300
CTNNB1 expression (H-score)
LEF-1
30
p = 0.4013
Number of samples [n]
20
10
0
1
2
3
4
ENSAT stage
☐ low
☒ intermediate
☒ high
A
FKBP5 low vs. high
15
FKBP5
log10(p-value)
10
5
MMP9
SLC26A11
IL1R1
CD206
0
-3
-2
-1
0
1
2
3
Log2 fold change
B
C
0.7472
0.2020
2500
2500
normalized counts
2000
normalized counts
2000
1500
:
1500
:
1000
1000
500
500
0
GC
0
inactive
GCA inactive
D
0.3617
2500
normalized counts
2000
1500
:
1000
500
0
GC+GCA
inactive